Metabolmics Could Transform the Future of Cannabis Medicine
Why is cannabis beneficial for some people or ailments and not others? Is it due to some special methods of consumption, formulation, or frequency of use?
Juno Metabolomics, a company concerned with a personalized approach to medicine — or more specifically, with a response to therapy in individuals — might have an answer to this tantalizing question.
Dr. Tim Garrett, the co-founder of Juno Metabolomics, has recently spoken about his company’s efforts and what is being done with respect to medical cannabis. In addition, he offered public education on metabolomics itself and its capacity to change the future of medicine.
So, how can you personalize medicine?
Apparently, there are techniques that can be used to measure the unique molecular structure of individual people. For instance, take a look at pharmacogenomics where the genetic structure of an individual is utilized for a thorough understanding of how a specific person will respond to a certain drug.
Nevertheless, the question remains — how does metabolomics work?
As Dr. Garrett explains, the metabolome is a set of tiny molecules present in a person that is able to promptly indicate the response to any kind of stimulus — whether it be an active illness or treatment.
Additionally, the metabolome is made out of various types of molecules, such as amino acids, sugars, lipids, etc., and even exogenous metabolites that affect our health; for instance, the microbes in our guts. Measuring these metabolites in an unbiased way leads to a digital output of the current health status that can be used for personalized diagnostics.
Dr. Garret also adds that by applying such a metabolism-based scrutiny, science can provide evidence for multiple crucial points within the cannabis industry; for example, measuring the body’s response to cannabis-based treatment, determining the individual efficacy of cannabis, as well as the ability to identify various types of biochemical responses to different types of cannabis and its consumption.
Furthermore, by measuring individual metabolites, we are able to deduce just how the organism changes after the use of cannabis (e.g., in what way our neurotransmitters are affected), providing us with the evidence necessary for safe use. The greatest advantage of this method, however, is the ability to analyze patient test samples — taken up to a month after treatment — and still being able to indicate the proper biochemical evidence on a response to the treatment.
According to Dr. Garrett, they’re about to launch a new medical cannabis platform — JUNOKANA — which is a giant step toward expanding the technology of testing medical cannabis’s efficacy. What’s more, the ultimate goal of this platform would be clinical usage, in the near future, increasing public awareness on the true, evidence-based benefits of medical cannabis as a result of an innovative, scientific approach.